Pioneering study will establish the legal framework for genomic medicine
NIH has declared the adoption of genomic medicine by clinicians to be a top priority to improve both individual and public health. The federal Precision Medicine Initiative (PMI), announced by President Obama and currently being launched, aims to use genomics and other analyses to accelerate development of more powerful and tailored treatments for cancer and other diseases. Yet U.S. federal and state genomics law is unclear and poorly understood, presenting a major obstacle to progress.
As NIH Director Francis S. Collins, MD, and National Cancer Institute Director Harold Varmus, MD, have written, "Achieving the goals of precision medicine will . . . require advancing the nation's regulatory frameworks." Leading LawSeqSM is a team of three principal investigators:
- Susan M. Wolf, JD (University of Minnesota) is an expert on law, medicine and public policy who, for more than a decade, has led a succession of NIH-funded projects generating recommendations on return of research results and incidental findings in genomics.
- Ellen Wright Clayton, MD, JD (Vanderbilt University) is an expert on the ethical, legal and policy questions raised by genomics, who has led NIH-funded work on pediatric genomics and co- directs an NIH-funded Center of Excellence in Genomic Science.
- Frances Lawrenz, PhD (University of Minnesota) is an expert in qualitative and quantitative research methods who has successfully led multiple National Science Foundation grants and has directed qualitative research on managing incidental findings and return of genomic results.
These co-leaders will be joined by a group of 22 top experts - from academia, industry, and clinical care - who will collaborate over the course of this 3-year project to clarify current law, address gaps, and generate the forward-looking recommendations needed to create the legal foundation for successfully translating genomics into clinical care.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.